Crispr
Biomarker predicts poor response to CAR-T, points way to personalized, gene-edited therapy
Researchers have identified CD58 status as a predictive marker for durable responses to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
First patient treated with CRISPR medicine in phase 1/2 trial
Top stories in hematology/oncology: CRISPR-edited T cells safe in patients with cancer, FDA grants another priority review to Keytruda
A study presented at the American Society of Hematology’s Meeting and Exposition found that cells genetically edited using CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared safe and feasible. This was among the week’s top stories in hematology/oncology.
CRISPR-edited T cells appear safe for patients with cancer
ORLANDO — Immune cells genetically edited with CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared to be safe and represent a feasible therapeutic approach, according to results of a prospective phase 1 study presented at ASH Annual Meeting and Exposition.